Results for this period
First quarter1 January 2026–31 March 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Increase in the number of milestones achieved (from 1 in the same period of the previous year to 7 in the current period), strong sales of Pivlaz® and Quviviq®, and lower research and development expenses and selling, general and administrative expenses. Restructuring costs and impairment losses were also recorded.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–31 March 2026 |
| Net Sales | ¥11,256 million (YoY +69.4%) |
| Operating profit | ¥3,244 million |
| Ordinary income | ¥3,043 million |
| Profit attributable to owners of the parent | ¥1,793 million |
| Net income per share | ¥19.82 |
| Equity ratio | End of the current fiscal period 47.8 / End of previous period 45.3 |
| Total assets | ¥133,338 million |
| Net assets | ¥63,686 million |
| Cash flows from operating activities | ¥-1,654 million |
| Cash flows from investing activities | ¥-5,461 million |
| Cash flows from financing activities | ¥-1,672 million |
| Cash and cash equivalents at end of period | ¥11,597 million |
| Full-year earnings forecast | Net Sales 33,800～48,800 / Operating profit 700～15,700 / Ordinary income Not disclosed / Net income Not disclosed |
| Annual Dividend Forecast | ¥0 → ¥0（0%） |
| Depreciation and amortization | ¥433 million |
| Impairment loss | ¥277 million |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name None |
| Material subsequent events | At a meeting of the Board of Directors held on 15 April 2026, the company resolved to issue new shares under its RSU plan and in connection with the introduction of a retirement-type stock benefit trust (J-ESOP). |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 90,496,735 |
| Treasury Shares at Period-End | 1,981 |
| Factors Behind Changes in Business Performance | Increase in the number of milestones achieved (from 1 in the same period of the previous year to 7 in the current period), strong sales of Pivlaz® and Quviviq®, and lower research and development expenses and selling, general and administrative expenses. Restructuring costs and impairment losses were also recorded. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased as milestone income from existing partners rose from 1 project in the same period of the previous year to 7 projects in the current period, and sales of Pivlaz® and Quviviq® were strong. Operating profit improved due to higher revenue, as well as lower research and development expenses and selling, general and administrative expenses. The company also recorded ¥469 million in restructuring costs and ¥277 million in impairment losses.